1. Clinical Overview
Garenoxacin is a novel, broad-spectrum des-F(6)-quinolone antibacterial agent, distinct from fluoroquinolones. It is a pyridone carboxylic acid derivative with potent activity against a wide range of Gram-positive, Gram-negative, and atypical pathogens, including quinolone-resistant strains. It is indicated for the treatment of community-acquired respiratory and skin infections. Its unique structure reduces the risk of phototoxicity and potential for QT prolongation compared to older quinolones.
| Onset | Duration | Bioavailability |
|---|---|---|
| Rapid absorption leads to detectable serum levels within 0.5-1 hour. Clinical symptom improvement is typically observed within 48-72 hours of initiating therapy. | Approximately 24 hours, supporting once-daily dosing due to its long half-life. | Approximately 90-95% following oral administration. |
2. Mechanism of Action
Garenoxacin is a potent inhibitor of two essential bacterial type II topoisomerase enzymes: DNA gyrase (primarily in Gram-negative bacteria) and topoisomerase IV (primarily in Gram-positive bacteria). It binds to the enzyme-DNA complex, stabilizing it and preventing the religation of DNA strands after double-strand breakage. This leads to rapid, bactericidal cell death.
3. Indications & Uses
- Community-Acquired Pneumonia (CAP) caused by Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Moraxella catarrhalis
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by S. pneumoniae, H. influenzae, M. catarrhalis
- Uncomplicated Skin and Skin Structure Infections (uSSSI) caused by Staphylococcus aureus (methicillin-susceptible), Streptococcus pyogenes
4. Dosage & Administration
Adult Dosage: 400 mg orally once daily. For the 200mg tablet: Two tablets (200mg each) taken together once daily. Duration: CAP - 7-14 days; ABECB - 5-10 days; uSSSI - 7-10 days.
Administration: Administer orally, with or without food. The tablet should be swallowed whole with a full glass of water. Do not crush or chew. Maintain adequate hydration. Avoid concurrent administration with multivalent cation-containing products (antacids, iron, zinc, sucralfate, dairy products). Administer garenoxacin at least 2 hours before or 4 hours after these products.
5. Side Effects
Common side effects may include:
- Nausea
- Diarrhea
- Headache
- Dizziness
- Insomnia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Antacids (Al, Mg), Sucralfate, Iron, Zinc | Markedly reduced absorption of Garenoxacin due to chelation | Major |
| Warfarin | Potential increase in INR and risk of bleeding; monitor INR closely | Moderate |
| NSAIDs (e.g., Ibuprofen) | Increased risk of CNS stimulation and seizures | Moderate |
| Corticosteroids (e.g., Prednisolone) | Increased risk of tendon rupture, especially in elderly | Moderate |
| Anti-diabetic agents (Sulfonylureas, Insulin) | May potentiate hypoglycemic effect; monitor blood glucose | Moderate |
| Other QT-prolonging drugs (e.g., Amiodarone, Sotalol, Macrolides, TCAs) | Additive effect on QT prolongation, increasing risk of arrhythmias | Major |
| Probenecid | Reduces renal tubular secretion of Garenoxacin, increasing its plasma levels | Moderate |
7. Patient Counselling
- DO complete the full course of therapy even if you feel better.
- DO take the tablet with a full glass of water.
- DO maintain adequate fluid intake.
- DO inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- DO NOT take antacids, iron, zinc, or multivitamins within 2 hours before or 4 hours after taking Garenoxacin.
- DO NOT crush or chew the tablet.
- DO NOT share your medication with others.
8. Toxicology & Storage
Overdose: Symptoms may include nausea, vomiting, dizziness, headache, and seizures. Crystalluria with renal toxicity may occur with massive overdose.
Storage: Store below 30°C, in a cool, dry place. Protect from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.